ヒトパピローマウイルスワクチン市場 - 世界の産業規模、シェア、動向、機会、および予測、2018年-2028年価数別(2価、4価、非価、その他)、適応疾患別(子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、その他)、流通チャネル別(病院・クリニック、政府機関・非政府機関、官民アライアンス、その他)、地域別、競争相手別Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Region, and By Competition ヒトパピローマウイルスワクチンの世界市場は、予測期間2024-2028年に目覚ましい成長を遂げると予測されている。ヒトパピローマウイルスウイルス関連疾患の増加、ヒトパピローマウイルスに関連する世界的な認知を... もっと見る
サマリーヒトパピローマウイルスワクチンの世界市場は、予測期間2024-2028年に目覚ましい成長を遂げると予測されている。ヒトパピローマウイルスウイルス関連疾患の増加、ヒトパピローマウイルスに関連する世界的な認知を広めるための政府および民間組織によるイニシアチブの増加が、市場の成長を促進しています。ヒトパピローマウイルス感染症は、子宮頸がん、陰茎がん、性器がんなど、ヒトパピローマウイルス関連がんに起因する最も一般的な性感染症です。ヒトパピローマウイルスワクチンは、特定のタイプのヒトパピローマウイルスから保護する予防接種です。このワクチンは、2種類、4種類、または9種類のヒトパピローマウイルスから保護する。市場の成長を支える要因としては、治療用ワクチン開発のための研究の増加、多数の臨床試験、認知度の向上と政府投資、ヒトパピローマウイルス感染を減らすニーズの高まりなどが挙げられる。clinical trials.govによると、2022年11月現在、世界中でヒトパピローマウイルスワクチンに関連する約394の臨床研究がさまざまな開発段階にある。ヒトパピローマウイルス疾患の症例の増加 肛門、口腔咽頭、生殖器などの異なる器官におけるヒトパピローマウイルス関連疾患の症例の急増は、ヒトパピローマウイルスワクチンの需要を著しく高め、それによって市場成長の有利な機会を生み出している。市場には、二価、四価、非価の3種類のワクチンがある。この3種類のワクチンはいずれも、子宮頸がん患者の70%を治癒させるウイルス16型と18型の感染を避けるのに非常に有効である。米国疾病予防管理センター(CDC)によると、米国ではヒトパピローマウイルスは最も一般的な性感染症である。外陰・膣疾患の70%以上、陰茎悪性腫瘍の60%、肛門癌と子宮頸部腫瘍の90%がヒトパピローマウイルスが原因である。さらに、女性の場合、子宮頸がんは9歳から30歳の間に非常に多く、HPVワクチンの必要性に拍車をかけている。例えば、WHOによると、2017年、子宮頸がんによる女性の死亡者数は世界で250万人を超え、その85%は発展途上国で発生している。 政府・民間団体による取り組みの増加 過去数年にわたり、さまざまな国の政府や民間団体は、国民の間でパピローマウイルスに関する意識を醸成するためにいくつかの措置を講じており、それによってヒトパピローマウイルスワクチン市場の成長を促進している。その結果、ヒトパピローマウイルスワクチンに関連する研究開発活動や製品の発売が増加している。例えば、最近インドでは、子宮頸がんに対する初の4価ヒトパピローマウイルスワクチン(qHPV)が発売された。また、プロフェクタス・バイオサイエンシズ社は、HPV治療ワクチンであるGeneVax prime/VesiculoVaxを開発中である。このワクチンは7種類のヒトパピローマウイルスに効果があると考えられている。さらに、ユニセフを中心とする組織は、長年にわたりワクチンの受容性を向上させる努力をしてきた。汎米保健機構(PAHO)の回転基金とユニセフの供給部門の影響により、様々な国にとって予防接種がより低価格で入手できるようになっている。 市場区分 ヒトパピローマウイルスワクチンの世界市場は、価数、適応疾患、流通チャネル、企業に区分される。価数により、市場は2価、4価、非価、その他に分けられる。適応症別では、子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、その他に分類される。販売チャネルに基づくと、市場は病院・クリニック、政府・非政府組織、公的・民間連合、その他に区分される。国別では、米国はヒトパピローマウイルス関連疾患の有病率が上昇していること、医療インフラが整備されていることから、予測期間において有利な市場になると予想される。 市場プレイヤー Serum Institute of India Pvt. Ltd.、GlaxoSmithKline Plc.、Johnson & Johnson、Merck & Co., Inc.、AstraZeneca Plc.、Novartis AG、Inovio Pharmaceuticals, Inc.、Xenetic Biosciences, Inc.、Sanofi SA、Bharat Biotech International Limitedなどが市場で事業を展開する大手企業である。 報告書の範囲 本レポートでは、ヒトパピローマウイルスワクチンの世界市場を、業界動向に加えて、以下のカテゴリーに分類しています: - ヒトパピローマウイルスワクチン市場、価数別 o 2価 o 4価 o 非価 o その他 - ヒトパピローマウイルスワクチン市場:適応疾患別 o 子宮頸がん o 肛門がん o 膣がん o 陰茎癌 o 外陰癌 o その他 - ヒトパピローマウイルスワクチン市場:流通チャネル別 o 病院&クリニック o 政府・非政府組織 o 公的機関および民間連合 o その他 - ヒトパピローマウイルスワクチン市場:地域別 o 北米 米国 カナダ メキシコ o ヨーロッパ ドイツ フランス イギリス スペイン イタリア o アジア太平洋 中国 インド 日本 オーストラリア 韓国 南米 ブラジル アルゼンチン コロンビア o 中東・アフリカ 南アフリカ サウジアラビア UAE 競争環境 企業プロフィール:ヒトパピローマウイルスワクチン市場に参入している主要企業の詳細分析 利用可能なカスタマイズ: TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。このレポートでは以下のカスタマイズが可能です: 企業情報 - 追加市場参入企業(最大5社)の詳細分析とプロファイリング 目次1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Clinical Trial Analysis 5.1. Ongoing Clinical Trials 5.2. Completed Clinical Trials 5.3. Terminated Clinical Trials 5.4. Breakdown of Pipeline, By Development Phase 5.5. Breakdown of Pipeline, By Status 5.6. Breakdown of Pipeline, By Study Application 5.7. Breakdown of Pipeline, By Region 5.8. Clinical Trials Heat Map 6. Patent Analysis 7. Global Human Papillomavirus Vaccine Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others) 7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others) 7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others) 7.2.4. By Region 7.2.5. By Company (2022) 7.3. Market Map 7.3.1. By Valence 7.3.2. By Disease Indication 7.3.3. By Distribution Channel 7.3.4. By Region 8. North America Human Papillomavirus Vaccine Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Valence 8.2.2. By Disease Indication 8.2.3. By Distribution Channel 8.2.4. By Country 8.3. North America: Country Analysis 8.3.1. United States Human Papillomavirus Vaccine Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Valence 8.3.1.2.2. By Disease Indication 8.3.1.2.3. By Distribution Channel 8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Valence 8.3.2.2.2. By Disease Indication 8.3.2.2.3. By Distribution Channel 8.3.3. Canada Human Papillomavirus Vaccine Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Valence 8.3.3.2.2. By Disease Indication 8.3.3.2.3. By Distribution Channel 9. Europe Human Papillomavirus Vaccine Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Valence 9.2.2. By Disease Indication 9.2.3. By Distribution Channel 9.2.4. By Country 9.3. Europe: Country Analysis 9.3.1. France Human Papillomavirus Vaccine Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Valence 9.3.1.2.2. By Disease Indication 9.3.1.2.3. By Distribution Channel 9.3.2. Germany Human Papillomavirus Vaccine Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Valence 9.3.2.2.2. By Disease Indication 9.3.2.2.3. By Distribution Channel 9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Valence 9.3.3.2.2. By Disease Indication 9.3.3.2.3. By Distribution Channel 9.3.4. Italy Human Papillomavirus Vaccine Market Outlook 9.3.4.1. Market Size & Forecast 9.3.4.1.1. By Value 9.3.4.2. Market Share & Forecast 9.3.4.2.1. By Valence 9.3.4.2.2. By Disease Indication 9.3.4.2.3. By Distribution Channel 9.3.5. Spain Human Papillomavirus Vaccine Market Outlook 9.3.5.1. Market Size & Forecast 9.3.5.1.1. By Value 9.3.5.2. Market Share & Forecast 9.3.5.2.1. By Valence 9.3.5.2.2. By Disease Indication 9.3.5.2.3. By Distribution Channel 10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Valence 10.2.2. By Disease Indication 10.2.3. By Distribution Channel 10.2.4. By Country 10.3. Asia-Pacific: Country Analysis 10.3.1. China Human Papillomavirus Vaccine Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Valence 10.3.1.2.2. By Disease Indication 10.3.1.2.3. By Distribution Channel 10.3.2. India Human Papillomavirus Vaccine Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Valence 10.3.2.2.2. By Disease Indication 10.3.2.2.3. By Distribution Channel 10.3.3. Japan Human Papillomavirus Vaccine Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Valence 10.3.3.2.2. By Disease Indication 10.3.3.2.3. By Distribution Channel 10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook 10.3.4.1. Market Size & Forecast 10.3.4.1.1. By Value 10.3.4.2. Market Share & Forecast 10.3.4.2.1. By Valence 10.3.4.2.2. By Disease Indication 10.3.4.2.3. By Distribution Channel 10.3.5. Australia Human Papillomavirus Vaccine Market Outlook 10.3.5.1. Market Size & Forecast 10.3.5.1.1. By Value 10.3.5.2. Market Share & Forecast 10.3.5.2.1. By Valence 10.3.5.2.2. By Disease Indication 10.3.5.2.3. By Distribution Channel 11. South America Human Papillomavirus Vaccine Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Valence 11.2.2. By Disease Indication 11.2.3. By Distribution Channel 11.2.4. By Country 11.3. South America: Country Analysis 11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Valence 11.3.1.2.2. By Disease Indication 11.3.1.2.3. By Distribution Channel 11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Valence 11.3.2.2.2. By Disease Indication 11.3.2.2.3. By Distribution Channel 11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Valence 11.3.3.2.2. By Disease Indication 11.3.3.2.3. By Distribution Channel 12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook 12.1. Market Size & Forecast 12.1.1. By Value 12.2. Market Share & Forecast 12.2.1. By Valence 12.2.2. By Disease Indication 12.2.3. By Distribution Channel 12.2.4. By Country 12.3. MEA: Country Analysis 12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook 12.3.1.1. Market Size & Forecast 12.3.1.1.1. By Value 12.3.1.2. Market Share & Forecast 12.3.1.2.1. By Valence 12.3.1.2.2. By Disease Indication 12.3.1.2.3. By Distribution Channel 12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook 12.3.2.1. Market Size & Forecast 12.3.2.1.1. By Value 12.3.2.2. Market Share & Forecast 12.3.2.2.1. By Valence 12.3.2.2.2. By Disease Indication 12.3.2.2.3. By Distribution Channel 12.3.3. UAE Human Papillomavirus Vaccine Market Outlook 12.3.3.1. Market Size & Forecast 12.3.3.1.1. By Value 12.3.3.2. Market Share & Forecast 12.3.3.2.1. By Valence 12.3.3.2.2. By Disease Indication 12.3.3.2.3. By Distribution Channel 13. Market Dynamics 13.1. Drivers 13.2. Challenges 14. Market Trends & Developments 14.1. Recent Developments 14.2. Mergers & Acquisitions 14.3. Product Launches 15. Competitive Landscape 15.1. Business Overview 15.2. Company Snapshot 15.3. Products & Services 15.4. Financials (As reported) 15.5. Recent Developments 15.6. SWOT Analysis 15.6.1. Serum Institute of India Pvt. Ltd. 15.6.2. GlaxoSmithKline Plc. 15.6.3. Johnson & Johnson 15.6.4. Merck & Co., Inc. 15.6.5. AstraZeneca Plc 15.6.6. Novartis AG 15.6.7. Inovio Pharmaceuticals, Inc. 15.6.8. Xenetic Biosciences, Inc. 15.6.9. Sanofi SA 15.6.10. Bharat Biotech International Limited 16. Strategic Recommendations
SummaryGlobal human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide, are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain types of human papillomavirus. It protects against either two, four, or nine kinds of Human Papillomavirus Virus. The factors supporting the market’s growth are the increasing research for the development of therapeutic vaccines, the large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe. Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Clinical Trial Analysis 5.1. Ongoing Clinical Trials 5.2. Completed Clinical Trials 5.3. Terminated Clinical Trials 5.4. Breakdown of Pipeline, By Development Phase 5.5. Breakdown of Pipeline, By Status 5.6. Breakdown of Pipeline, By Study Application 5.7. Breakdown of Pipeline, By Region 5.8. Clinical Trials Heat Map 6. Patent Analysis 7. Global Human Papillomavirus Vaccine Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others) 7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others) 7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others) 7.2.4. By Region 7.2.5. By Company (2022) 7.3. Market Map 7.3.1. By Valence 7.3.2. By Disease Indication 7.3.3. By Distribution Channel 7.3.4. By Region 8. North America Human Papillomavirus Vaccine Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Valence 8.2.2. By Disease Indication 8.2.3. By Distribution Channel 8.2.4. By Country 8.3. North America: Country Analysis 8.3.1. United States Human Papillomavirus Vaccine Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Valence 8.3.1.2.2. By Disease Indication 8.3.1.2.3. By Distribution Channel 8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Valence 8.3.2.2.2. By Disease Indication 8.3.2.2.3. By Distribution Channel 8.3.3. Canada Human Papillomavirus Vaccine Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Valence 8.3.3.2.2. By Disease Indication 8.3.3.2.3. By Distribution Channel 9. Europe Human Papillomavirus Vaccine Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Valence 9.2.2. By Disease Indication 9.2.3. By Distribution Channel 9.2.4. By Country 9.3. Europe: Country Analysis 9.3.1. France Human Papillomavirus Vaccine Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Valence 9.3.1.2.2. By Disease Indication 9.3.1.2.3. By Distribution Channel 9.3.2. Germany Human Papillomavirus Vaccine Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Valence 9.3.2.2.2. By Disease Indication 9.3.2.2.3. By Distribution Channel 9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Valence 9.3.3.2.2. By Disease Indication 9.3.3.2.3. By Distribution Channel 9.3.4. Italy Human Papillomavirus Vaccine Market Outlook 9.3.4.1. Market Size & Forecast 9.3.4.1.1. By Value 9.3.4.2. Market Share & Forecast 9.3.4.2.1. By Valence 9.3.4.2.2. By Disease Indication 9.3.4.2.3. By Distribution Channel 9.3.5. Spain Human Papillomavirus Vaccine Market Outlook 9.3.5.1. Market Size & Forecast 9.3.5.1.1. By Value 9.3.5.2. Market Share & Forecast 9.3.5.2.1. By Valence 9.3.5.2.2. By Disease Indication 9.3.5.2.3. By Distribution Channel 10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Valence 10.2.2. By Disease Indication 10.2.3. By Distribution Channel 10.2.4. By Country 10.3. Asia-Pacific: Country Analysis 10.3.1. China Human Papillomavirus Vaccine Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Valence 10.3.1.2.2. By Disease Indication 10.3.1.2.3. By Distribution Channel 10.3.2. India Human Papillomavirus Vaccine Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Valence 10.3.2.2.2. By Disease Indication 10.3.2.2.3. By Distribution Channel 10.3.3. Japan Human Papillomavirus Vaccine Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Valence 10.3.3.2.2. By Disease Indication 10.3.3.2.3. By Distribution Channel 10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook 10.3.4.1. Market Size & Forecast 10.3.4.1.1. By Value 10.3.4.2. Market Share & Forecast 10.3.4.2.1. By Valence 10.3.4.2.2. By Disease Indication 10.3.4.2.3. By Distribution Channel 10.3.5. Australia Human Papillomavirus Vaccine Market Outlook 10.3.5.1. Market Size & Forecast 10.3.5.1.1. By Value 10.3.5.2. Market Share & Forecast 10.3.5.2.1. By Valence 10.3.5.2.2. By Disease Indication 10.3.5.2.3. By Distribution Channel 11. South America Human Papillomavirus Vaccine Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Valence 11.2.2. By Disease Indication 11.2.3. By Distribution Channel 11.2.4. By Country 11.3. South America: Country Analysis 11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Valence 11.3.1.2.2. By Disease Indication 11.3.1.2.3. By Distribution Channel 11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Valence 11.3.2.2.2. By Disease Indication 11.3.2.2.3. By Distribution Channel 11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Valence 11.3.3.2.2. By Disease Indication 11.3.3.2.3. By Distribution Channel 12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook 12.1. Market Size & Forecast 12.1.1. By Value 12.2. Market Share & Forecast 12.2.1. By Valence 12.2.2. By Disease Indication 12.2.3. By Distribution Channel 12.2.4. By Country 12.3. MEA: Country Analysis 12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook 12.3.1.1. Market Size & Forecast 12.3.1.1.1. By Value 12.3.1.2. Market Share & Forecast 12.3.1.2.1. By Valence 12.3.1.2.2. By Disease Indication 12.3.1.2.3. By Distribution Channel 12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook 12.3.2.1. Market Size & Forecast 12.3.2.1.1. By Value 12.3.2.2. Market Share & Forecast 12.3.2.2.1. By Valence 12.3.2.2.2. By Disease Indication 12.3.2.2.3. By Distribution Channel 12.3.3. UAE Human Papillomavirus Vaccine Market Outlook 12.3.3.1. Market Size & Forecast 12.3.3.1.1. By Value 12.3.3.2. Market Share & Forecast 12.3.3.2.1. By Valence 12.3.3.2.2. By Disease Indication 12.3.3.2.3. By Distribution Channel 13. Market Dynamics 13.1. Drivers 13.2. Challenges 14. Market Trends & Developments 14.1. Recent Developments 14.2. Mergers & Acquisitions 14.3. Product Launches 15. Competitive Landscape 15.1. Business Overview 15.2. Company Snapshot 15.3. Products & Services 15.4. Financials (As reported) 15.5. Recent Developments 15.6. SWOT Analysis 15.6.1. Serum Institute of India Pvt. Ltd. 15.6.2. GlaxoSmithKline Plc. 15.6.3. Johnson & Johnson 15.6.4. Merck & Co., Inc. 15.6.5. AstraZeneca Plc 15.6.6. Novartis AG 15.6.7. Inovio Pharmaceuticals, Inc. 15.6.8. Xenetic Biosciences, Inc. 15.6.9. Sanofi SA 15.6.10. Bharat Biotech International Limited 16. Strategic Recommendations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社の世界/地域別市場調査分野での最新刊レポート
本レポートと同じKEY WORD(vaccine)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|